Cytarabine + Daunorubicin ("7+3" Induction Chemotherapy)
Treatment for Acute Myeloid Leukemia
Typical Dosage: Cytarabine 100-200 mg/m² daily for 7 days; Daunorubicin 45-60 mg/m² daily for 3 days
Effectiveness
85%
Safety Score
25%
Clinical Trials
22
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Cytarabine 100-200 mg/m² daily for 7 days; Daunorubicin 45-60 mg/m² daily for 3 days
Time to Effect
3-4 weeks
Treatment Duration
Induction (7+3 days) then 3-4 consolidation cycles (total 4-6 months)
Evidence Quality
HIGHConfidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$3,000
Monitoring:$200,000
Side Effect Mgmt:$75,000
Total Annual:$278,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
2.5
Outcome-Based Costs
Cost per Responder
$397,143
Cost per Remission
$397,143
Cytarabine + Daunorubicin ("7+3" Induction Chemotherapy) Outcomes
for Acute Myeloid Leukemia
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+70%
Remission Rate
+70%
Common Side Effects
Myelosuppression (neutropenia, thrombocytopenia, anemia)
+100%
Infection/Febrile neutropenia
+60%
Nausea/Vomiting
+70%
Mucositis
+40%
Diarrhea
+40%
Cardiotoxicity (Daunorubicin)
+10%
Alopecia
+85%
Active Clinical Trials
7 active trials recruiting for Cytarabine + Daunorubicin ("7+3" Induction Chemotherapy) in Acute Myeloid Leukemia
A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
NCT06182592NOT YET RECRUITINGPHASE3
120 participants
INTERVENTIONAL
Tianjin, China
Started: Jan 1, 2024
Revumenib in Combination With 7+3 + Midostaurin in AML
NCT06313437RECRUITINGPHASE1
22 participants
INTERVENTIONAL
Boston, United States +1 more
Started: Dec 6, 2024
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
NCT05735184RECRUITINGPHASE1
420 participants
INTERVENTIONAL
Phoenix, United States +43 more
Started: Jul 18, 2023
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
NCT04385290RECRUITINGPHASE1, PHASE2
214 participants
INTERVENTIONAL
München, Germany +20 more
Started: Sep 4, 2020
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT05445154RECRUITINGPHASE1, PHASE2
58 participants
INTERVENTIONAL
Chengdu, China
Started: Aug 31, 2021
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
NCT05177731ACTIVE NOT RECRUITINGPHASE3
188 participants
INTERVENTIONAL
Suzhou, China
Started: Mar 1, 2022
Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study"
NCT05304156RECRUITING
200 participants
OBSERVATIONAL
Bobigny, France +1 more
Started: Apr 26, 2022
Completed Clinical Trials
9 completed trials for Cytarabine + Daunorubicin ("7+3" Induction Chemotherapy) in Acute Myeloid Leukemia
Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT00915252COMPLETEDPHASE2
214 participants
INTERVENTIONAL
Aachen, Germany +26 more
Started: Jul 1, 2009
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
NCT02560025COMPLETEDPHASE2
42 participants
INTERVENTIONAL
Boston, United States +1 more
Started: Dec 1, 2015
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
NCT03416179COMPLETEDPHASE3
730 participants
INTERVENTIONAL
Los Angeles, United States +148 more
Started: Apr 20, 2018
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
NCT02326584COMPLETEDPHASE1
116 participants
INTERVENTIONAL
Birmingham, United States +12 more
Started: Dec 1, 2014
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
NCT03379727COMPLETEDPHASE3
301 participants
INTERVENTIONAL
Pleven, Bulgaria +85 more
Started: Feb 13, 2018
Alisertib for Acute Myeloid Leukemia
NCT01779843COMPLETEDPHASE1
22 participants
INTERVENTIONAL
Boston, United States +2 more
Started: Apr 1, 2013
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
NCT02306291COMPLETEDPHASE1, PHASE2
91 participants
INTERVENTIONAL
Sacramento, United States +7 more
Started: Mar 1, 2015
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02835729COMPLETEDPHASE1
54 participants
INTERVENTIONAL
Augusta, United States +1 more
Started: Jul 1, 2016
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
NCT03226418COMPLETEDPHASE2
75 participants
INTERVENTIONAL
Omaha, United States
Started: Jul 7, 2017
Showing 20 of 22 total trials